Focused On-demand Library for Translocon-associated protein subunit delta

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P51571

UPID:

SSRD_HUMAN

Alternative names:

Signal sequence receptor subunit delta

Alternative UPACC:

P51571; A8K378; Q53XY1

Background:

The Translocon-associated protein subunit delta, also known as Signal sequence receptor subunit delta, plays a pivotal role in protein biosynthesis. It is part of the TRAP complex, crucial for binding calcium to the ER membrane, which in turn regulates the retention of ER resident proteins. This function is vital for proper protein folding and processing, impacting cell function and health.

Therapeutic significance:

The protein is linked to Congenital disorder of glycosylation 1Y, a multisystem disorder stemming from defects in glycoprotein biosynthesis. This association highlights the protein's critical role in embryonic development and cell function maintenance, suggesting that targeting this protein could lead to novel treatments for this congenital disorder and potentially other glycosylation-related diseases.